[go: up one dir, main page]

TR201819202A2 - A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT - Google Patents

A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT

Info

Publication number
TR201819202A2
TR201819202A2 TR2018/19202A TR201819202A TR201819202A2 TR 201819202 A2 TR201819202 A2 TR 201819202A2 TR 2018/19202 A TR2018/19202 A TR 2018/19202A TR 201819202 A TR201819202 A TR 201819202A TR 201819202 A2 TR201819202 A2 TR 201819202A2
Authority
TR
Turkey
Prior art keywords
agent
multiple sclerosis
combination containing
muscle relaxing
muscle
Prior art date
Application number
TR2018/19202A
Other languages
Turkish (tr)
Inventor
Toksöz Ahmet
Toksöz Zafer
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2018/19202A priority Critical patent/TR201819202A2/en
Priority to EP19894906.7A priority patent/EP3893855A4/en
Priority to PCT/TR2019/050960 priority patent/WO2020122839A2/en
Publication of TR201819202A2 publication Critical patent/TR201819202A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş, bir multipl skleroz ajanı ve en az bir kas gevşetici 5 ajan içeren bir farmasötik kombinasyon ile ilgilidir, burada multipl skleroz ajanı, teriflunomid veya fampiridindir.The present invention relates to a pharmaceutical combination comprising a multiple sclerosis agent and at least one muscle relaxant 5 agent, wherein the multiple sclerosis agent is teriflunomide or fampiridine.

TR2018/19202A 2018-12-12 2018-12-12 A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT TR201819202A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2018/19202A TR201819202A2 (en) 2018-12-12 2018-12-12 A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT
EP19894906.7A EP3893855A4 (en) 2018-12-12 2019-11-15 A combination comprising a multiple sclerosis agent and at least one muscle relaxant agent
PCT/TR2019/050960 WO2020122839A2 (en) 2018-12-12 2019-11-15 A combination comprising a multiple sclerosis agent and at least one muscle relaxant agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2018/19202A TR201819202A2 (en) 2018-12-12 2018-12-12 A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT

Publications (1)

Publication Number Publication Date
TR201819202A2 true TR201819202A2 (en) 2020-06-22

Family

ID=71075654

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/19202A TR201819202A2 (en) 2018-12-12 2018-12-12 A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT

Country Status (3)

Country Link
EP (1) EP3893855A4 (en)
TR (1) TR201819202A2 (en)
WO (1) WO2020122839A2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508715A (en) * 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
GEP20135986B (en) * 2009-03-09 2013-12-10 Shashikant Prabhudas Kurani Novel sustained release composition of compounds selected from class of centrally acting muscle relaxants
JP6735020B2 (en) 2014-11-04 2020-08-05 アダマス ファーマシューティカルズ， インコーポレイテッド Methods of administering amantadine compositions
WO2017031276A1 (en) * 2015-08-19 2017-02-23 The Regents Of The University Of California Methods of providing neuroprotective therapy related to administering an estrogen receptor beta ligand
CA3042956A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
TR201720406A2 (en) * 2017-12-14 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi COMBINATIONS CONTAINING A SKELETAL MUSCLE LOAER AND A MULTIPLE SCLEROSIS THERAPY

Also Published As

Publication number Publication date
EP3893855A2 (en) 2021-10-20
WO2020122839A3 (en) 2021-02-18
EP3893855A4 (en) 2022-08-17
WO2020122839A2 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MX2020005063A (en) KRAS G12C INHIBITORS.
CY1123678T1 (en) USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES
BR112018006259A2 (en) "compressible adjunct with intermediate support structures"
MX2018013983A (en) KRAS G12C INHIBITORS.
MX2024000349A (en) Compounds and uses thereof.
MX385269B (en) SULFONAMIDE COMPOUND OR SALT THEREOF.
CO2019011265A2 (en) Modulators of Pcsk9 Expression
CO2021004141A2 (en) Modulators of pnpla3 expression
MX2020012497A (en) Modulators of apol1 expression.
CO2022000270A2 (en) enzyme inhibitors
TR201819197A2 (en) A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent
MX2019008972A (en) Core-shell structure, preparation, medicine for external application, tape agent and cosmetic product.
TR201720406A2 (en) COMBINATIONS CONTAINING A SKELETAL MUSCLE LOAER AND A MULTIPLE SCLEROSIS THERAPY
PH12019502110A1 (en) Pharmaceutical combination comprising ponesimod
PH12020552158A1 (en) Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
BR112018014069A2 (en) use of a fasting and imitation fasting diet, use of a fasting and imitation fasting diet with a chemotherapeutic agent, and diet package.
TR201819202A2 (en) A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT
CO2020003134A2 (en) Modulators of enac expression
MA54222A (en) COMBINATION OF MCL-1 INHIBITOR AND MIDOSTAURIN, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
UY38472A (en) FOXP3 EXPRESSION MODULATORS
EA202191469A1 (en) RESTORATION USING ANTI-SENSE OLIGONUCLEOTIDES ABCA4 WITH ABERRANT SPLICING
TR201721824A2 (en) A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN
TR201720515A2 (en) A SOLID ORAL DOSAGE FORM CONTAINING LINAGLIPTIN
MA47198A (en) COMBINATION OF MCL-1 INHIBITOR AND TAXANE COMPOUND, ITS USES AND PHARMACEUTICAL COMPOSITIONS INCLUDING IT
BR112018072255A2 (en) azasteroids for tuberculosis treatment